{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:17:50Z","timestamp":1784074670162,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clml.2025.04.001","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:18:30Z","timestamp":1744150710000},"page":"615-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SOHO State of the Art Updates and Next Questions | Transplanting Hope: Managing Relapsed\/Refractory AML"],"prefix":"10.1016","volume":"25","author":[{"given":"Christopher Ronald","family":"Funk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0816-6729","authenticated-orcid":false,"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.04.001_bib0001","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1242\/dmm.015974","article-title":"Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?","volume":"7","author":"Grove","year":"2014","journal-title":"DMM Dis Models Mech"},{"key":"10.1016\/j.clml.2025.04.001_bib0002","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nrc3895","article-title":"DNMT3A in haematological malignancies","volume":"15","author":"Yang","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2025.04.001_bib0003","first-page":"1148","article-title":"Epigenetics in Cancer","volume":"358","author":"Esteller","year":"2008"},{"key":"10.1016\/j.clml.2025.04.001_bib0004","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"The Hallmarks of Cancer Review Evolve Progressively from Normalcy via a Series of Pre","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.clml.2025.04.001_bib0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.clml.2025.04.001_bib0006","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1046\/j.1365-2141.1997.4763281.x","article-title":"G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia","volume":"99","author":"Parker","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.04.001_bib0007","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.1992.10.7.1103","article-title":"A Phase III Trial Comparing Idarubicin and Daunorubicin in Combination with Cytarabine in Acute Myelogenous Leukemia: A Southeastern Cancer Study Group Study","volume":"10","author":"Vogler","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.04.001_bib0008","first-page":"7","article-title":"Venetoclax Combined with Decitabine or Azacitidine in Treatment-naive, Elderly Patients with Acute Myeloid Leukemia","volume":"133","author":"Dinardo","year":"2019"},{"key":"10.1016\/j.clml.2025.04.001_bib0009","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.04.001_bib0010","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.04.001_bib0011","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Ed. Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.04.001_bib0012","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/bloodadvances.2024013214","article-title":"Measurable residual disease as predictor of post\u2013day +100 relapses after allografting in adult AML","volume":"9","author":"Ali","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.04.001_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01217","article-title":"The graft-versus-leukemia effect in AML","volume":"9","author":"Sweeney","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2025.04.001_bib0014","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a Center for International blood and marrow Transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2025.04.001_bib0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3324\/haematol.2015.139105","article-title":"Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia","volume":"101","author":"Ossenkoppele","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.04.001_bib0016","doi-asserted-by":"crossref","first-page":"917.e1","DOI":"10.1016\/j.jtct.2024.06.021","article-title":"Current trends and outcomes in cellular therapy activity in the United States, including prospective patient-reported outcomes data collection in the Center for International Blood and Marrow Transplant Research Registry","volume":"30","author":"Cusatis","year":"2024","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.clml.2025.04.001_bib0017","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.04.001_bib0018","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/s41375-023-01981-2","article-title":"Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms","volume":"37","author":"Shih","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.04.001_bib0019","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.04.001_bib0020","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.04.001_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/jcm6060057","article-title":"Minimal residual disease in acute myeloid leukemia: still a work in progress?","volume":"6","author":"Mosna","year":"2017","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2025.04.001_bib0022","series-title":"Current Uses and Outcomes of Cellular Therapies in the US: CIBMTR Summary Slides","author":"Spellman","year":"2024"},{"key":"10.1016\/j.clml.2025.04.001_bib0023","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.04.001_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123210","article-title":"TP53 Mutations in AML patients are associated with dismal clinical outcome irrespective of frontline induction regimen and allogeneic hematopoietic cell transplantation","volume":"15","author":"Zhao","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.04.001_bib0025","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/cncr.34268","article-title":"Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia","volume":"128","author":"Loke","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.04.001_bib0026","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.04.001_bib0027","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2147\/CMAR.S339846","article-title":"Allogeneic stem cell transplantation with sequential melphalan-based conditioning in AML: residual morphological blast count determines the risk of relapse","volume":"14","author":"Sockel","year":"2022","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clml.2025.04.001_bib0028","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<105::AID-AJH3>3.0.CO;2-W","article-title":"Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia","volume":"58","author":"Montillo","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.04.001_bib0029","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2004.07.048","article-title":"Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)","volume":"22","author":"Greenberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.04.001_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14082025","article-title":"Azacitidine plus Venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients","volume":"14","author":"Garciaz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.04.001_bib0031","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.2021011583","article-title":"Follow-up of patients with R\/R FLT3-mutation\u2013positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","volume":"139","author":"Perl","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.04.001_bib0032","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","article-title":"Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib","volume":"6","author":"Smith","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.04.001_bib0033","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.04.001_bib0034","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2022-159962","volume":"140","author":"Stelljes","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.04.001_bib0035","article-title":"Menin inhibition with Revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","author":"Issa","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.04.001_bib0036","doi-asserted-by":"crossref","first-page":"38.e1","DOI":"10.1016\/j.jtct.2022.09.003","article-title":"Impact on outcome of minimal residual disease after hematopoietic stem cell transplantation with fludarabine, Amsacrine, and cytosine arabinoside-busulfan conditioning: a retrospective monocentric study","volume":"29","author":"Le Meur","year":"2023","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.clml.2025.04.001_bib0037","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.04.001_bib0038","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41409-022-01611-y","article-title":"Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed\/refractory acute myeloid leukemia: an EBMT analysis","volume":"57","author":"Rodr\u00edguez-Arbol\u00ed","year":"2022","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2025.04.001_bib0039","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0727-4","volume":"12","author":"Saraceni","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2025.04.001_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16030532","article-title":"Smart conditioning with venetoclax-enhanced sequential FLAMSA + RIC in patients with high-risk myeloid malignancies","volume":"16","author":"Schulz","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.04.001_bib0041","article-title":"Randomized phase III SIERRA trial of 131I-Apamistamab before allogeneic hematopoietic cell transplantation versus conventional care for relapsed\/refractory AML","author":"Gyurkocza","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.04.001_bib0042","doi-asserted-by":"crossref","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes\u2014Long-term follow-Up of the BMT CTN 0901 clinical trial: B. Scott et al","volume":"27","author":"Scott","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.clml.2025.04.001_bib0043","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbmt.2010.05.007","article-title":"Conditioning with Treosulfan and Fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies","volume":"17","author":"Nemecek","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2025.04.001_bib0044","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bmt.1705965","article-title":"High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission","volume":"41","author":"Schmid","year":"2008","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2025.04.001_bib0045","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.04.001_bib0046","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1182\/blood-2023-188162","article-title":"Phase 1 trial results for patients with advanced hematologic malignancies undergoing reduced intensity allogeneic HCT with Orca-T donor cell therapy product and single agent Tacrolimus","volume":"142","author":"Villar-Prados","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.04.001_bib0047","series-title":"EBMT 51st Annual Meeting","author":"Meyer","year":"2025"},{"key":"10.1016\/j.clml.2025.04.001_bib0048","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127244","article-title":"Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients","volume":"4","author":"Meyer","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.clml.2025.04.001_bib0049","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/bloodadvances.2020002444","article-title":"ab T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies","volume":"5","author":"De Witte","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.04.001_bib0050","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41409-021-01232-x","article-title":"Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of \u03b1\u03b2 T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia","volume":"56","author":"Dunaikina","year":"2021","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.clml.2025.04.001_bib0051","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.04.001_bib0052","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/bloodadvances.2018028332","article-title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","volume":"3","author":"Cooley","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.04.001_bib0053","doi-asserted-by":"crossref","unstructured":"I Tawara, S Kageyama, Y Miyahara, et al. Safety and persistence of WT1-specific T-cell receptor gene2transduced lymphocytes in patients with AML and MDS. 130, 1985\u20131994 (2017).","DOI":"10.1182\/blood-2017-06-791202"},{"key":"10.1016\/j.clml.2025.04.001_bib0054","first-page":"234","article-title":"Venetoclax Enhances T Cell-mediated Antileukemic Activity by Increasing ROS Production","volume":"138","author":"Lee","year":"2021"},{"key":"10.1016\/j.clml.2025.04.001_bib0055","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1182\/blood-2024-210956","article-title":"Outcomes of hypomethylating agents\/venetoclax (HMA\/VEN) treatment for relapse of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after allogeneic hematopoietic Cell transplant (alloHCT)","volume":"144","author":"Samuels","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.04.001_bib0056","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.04.001_bib0057","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clml.2024.02.005","article-title":"Hypomethylating agents and venetoclax for acute myeloid leukemia relapsed after hematopoietic stem cell transplant","volume":"24","author":"Ionescu","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.04.001_bib0058","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00277-020-04321-x","volume":"100","author":"Schuler","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2025.04.001_bib0059","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/ajh.25859","article-title":"The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia","volume":"95","author":"Byrne","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.04.001_bib0060","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.transci.2016.05.011","article-title":"Donor lymphocyte infusion after allogeneic stem cell transplantation","volume":"54","author":"Castagna","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.clml.2025.04.001_bib0061","unstructured":"A Burchert, G Bug, LV Fritz, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN) (2020; https:\/\/doi.org\/10.1200\/JCO.19.03345)."},{"key":"10.1016\/j.clml.2025.04.001_bib0062","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.04.001_bib0063","doi-asserted-by":"crossref","first-page":"10561","DOI":"10.1182\/blood-2022-159312","article-title":"Phase II trial of venetoclax (Ven) in combination with Azacitidine (AZA) as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation (SCT)","volume":"140","author":"Oran","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.04.001_bib0064","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","article-title":"Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies","volume":"6","author":"Fathi","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.04.001_bib0065","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.04.001_bib0066","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbmt.2013.02.005","article-title":"Finding the sweet spot for donor lymphocyte infusions","volume":"19","author":"Yun","year":"2013","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T03:14:50Z","timestamp":1755746090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":66,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2152265025001120"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Transplanting Hope: Managing Relapsed\/Refractory AML","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}